首页 > 最新文献

European Radiology最新文献

英文 中文
Robustness of radiomics among photon-counting detector CT and dual-energy CT systems: a texture phantom study. 光子计数探测器 CT 和双能量 CT 系统放射组学的鲁棒性:纹理模型研究。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-07-24 DOI: 10.1007/s00330-024-10976-1
Lan Zhu, Haipeng Dong, Jing Sun, Lingyun Wang, Yue Xing, Yangfan Hu, Junjie Lu, Jiarui Yang, Jingshen Chu, Chao Yan, Fei Yuan, Jingyu Zhong

Objectives: To evaluate the robustness of radiomics features among photon-counting detector CT (PCD-CT) and dual-energy CT (DECT) systems.

Methods: A texture phantom consisting of twenty-eight materials was scanned with one PCD-CT and four DECT systems (dual-source, rapid kV-switching, dual-layer, and sequential scanning) at three dose levels twice. Thirty sets of virtual monochromatic images at 70 keV were reconstructed. Regions of interest were delineated for each material with a rigid registration. Ninety-three radiomics were extracted per PyRadiomics. The test-retest repeatability between repeated scans was assessed by Bland-Altman analysis. The intra-system reproducibility between dose levels, and inter-system reproducibility within the same dose level, were evaluated by intraclass correlation coefficient (ICC) and concordance correlation coefficient (CCC). Inter-system variability among five scanners was assessed by coefficient of variation (CV) and quartile coefficient of dispersion (QCD).

Results: The test-retest repeatability analysis presented that 97.1% of features were repeatable between scan-rescans. The mean ± standard deviation ICC and CCC were 0.945 ± 0.079 and 0.945 ± 0.079 for intra-system reproducibility, respectively, and 86.0% and 85.7% of features were with ICC > 0.90 and CCC > 0.90, respectively, between different dose levels. The mean ± standard deviation ICC and CCC were 0.157 ± 0.174 and 0.157 ± 0.174 for inter-system reproducibility, respectively, and none of the features were with ICC > 0.90 or CCC > 0.90 within the same dose level. The inter-system variability suggested that 6.5% and 12.8% of features were with CV < 10% and QCD < 10%, respectively, among five CT systems.

Conclusion: The radiomics features were non-reproducible with significant variability in values among different CT techniques.

Clinical relevance statement: Radiomics features are non-reproducible with significant variability in values among photon-counting detector CT and dual-energy CT systems, necessitating careful attention to improve the cross-system generalizability of radiomic features before implementation of radiomics analysis in clinical routine.

Key points: CT radiomics stability should be guaranteed before the implementation in the clinical routine. Radiomics robustness was on a low level among photon-counting detectors and dual-energy CT techniques. Limited inter-system robustness of radiomic features may impact the generalizability of models.

目的评估光子计数探测器 CT(PCD-CT)和双能量 CT(DECT)系统的放射组学特征的稳健性:用一种 PCD-CT 和四种 DECT 系统(双源、快速 kV 切换、双层和顺序扫描)在三种剂量水平下对由 28 种材料组成的纹理模型进行了两次扫描。重建了 30 组 70 千伏的虚拟单色图像。每种材料的感兴趣区都是通过刚性配准来划定的。每个 PyRadiomics 提取了 93 个放射组。通过布兰-阿尔特曼分析评估了重复扫描之间的测试重复性。通过类内相关系数(ICC)和一致性相关系数(CCC)评估了不同剂量水平的系统内重复性和同一剂量水平的系统间重复性。五台扫描仪之间的系统间变异性通过变异系数(CV)和四分位离散系数(QCD)进行评估:结果:测试-重复性分析表明,97.1%的特征在扫描-扫描之间具有重复性。系统内重复性的平均±标准偏差 ICC 和 CCC 分别为 0.945 ± 0.079 和 0.945 ± 0.079,不同剂量水平之间分别有 86.0% 和 85.7% 的特征 ICC > 0.90 和 CCC > 0.90。系统间重现性的 ICC 和 CCC 平均值(± 标准差)分别为 0.157 ± 0.174 和 0.157 ± 0.174,在同一剂量水平内,没有任何特征的 ICC > 0.90 或 CCC > 0.90。系统间变异性表明,分别有 6.5% 和 12.8% 的特征具有 CV:放射组学特征是不可再现的,不同 CT 技术之间的数值存在显著差异:放射组学特征不可再现,不同光子计数探测器 CT 和双能量 CT 系统的特征值差异显著,因此在临床常规实施放射组学分析之前,有必要仔细关注提高放射组学特征的跨系统通用性:要点:在临床常规应用之前,应确保 CT 放射组学的稳定性。光子计数探测器和双能量 CT 技术的放射组学稳健性较低。放射组学特征的系统间稳健性有限,可能会影响模型的通用性。
{"title":"Robustness of radiomics among photon-counting detector CT and dual-energy CT systems: a texture phantom study.","authors":"Lan Zhu, Haipeng Dong, Jing Sun, Lingyun Wang, Yue Xing, Yangfan Hu, Junjie Lu, Jiarui Yang, Jingshen Chu, Chao Yan, Fei Yuan, Jingyu Zhong","doi":"10.1007/s00330-024-10976-1","DOIUrl":"10.1007/s00330-024-10976-1","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the robustness of radiomics features among photon-counting detector CT (PCD-CT) and dual-energy CT (DECT) systems.</p><p><strong>Methods: </strong>A texture phantom consisting of twenty-eight materials was scanned with one PCD-CT and four DECT systems (dual-source, rapid kV-switching, dual-layer, and sequential scanning) at three dose levels twice. Thirty sets of virtual monochromatic images at 70 keV were reconstructed. Regions of interest were delineated for each material with a rigid registration. Ninety-three radiomics were extracted per PyRadiomics. The test-retest repeatability between repeated scans was assessed by Bland-Altman analysis. The intra-system reproducibility between dose levels, and inter-system reproducibility within the same dose level, were evaluated by intraclass correlation coefficient (ICC) and concordance correlation coefficient (CCC). Inter-system variability among five scanners was assessed by coefficient of variation (CV) and quartile coefficient of dispersion (QCD).</p><p><strong>Results: </strong>The test-retest repeatability analysis presented that 97.1% of features were repeatable between scan-rescans. The mean ± standard deviation ICC and CCC were 0.945 ± 0.079 and 0.945 ± 0.079 for intra-system reproducibility, respectively, and 86.0% and 85.7% of features were with ICC > 0.90 and CCC > 0.90, respectively, between different dose levels. The mean ± standard deviation ICC and CCC were 0.157 ± 0.174 and 0.157 ± 0.174 for inter-system reproducibility, respectively, and none of the features were with ICC > 0.90 or CCC > 0.90 within the same dose level. The inter-system variability suggested that 6.5% and 12.8% of features were with CV < 10% and QCD < 10%, respectively, among five CT systems.</p><p><strong>Conclusion: </strong>The radiomics features were non-reproducible with significant variability in values among different CT techniques.</p><p><strong>Clinical relevance statement: </strong>Radiomics features are non-reproducible with significant variability in values among photon-counting detector CT and dual-energy CT systems, necessitating careful attention to improve the cross-system generalizability of radiomic features before implementation of radiomics analysis in clinical routine.</p><p><strong>Key points: </strong>CT radiomics stability should be guaranteed before the implementation in the clinical routine. Radiomics robustness was on a low level among photon-counting detectors and dual-energy CT techniques. Limited inter-system robustness of radiomic features may impact the generalizability of models.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"871-884"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases. 酰胺质子转移成像在区分胶质瘤和转移瘤的真正进展与治疗相关变化方面的性能。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-08-12 DOI: 10.1007/s00330-024-11004-y
Rajeev A Essed, Yeva Prysiazhniuk, Ivar J Wamelink, Aynur Azizova, Vera C Keil

Objectives: Differentiating true progression or recurrence (TP/TR) from therapy-related changes (TRC) is complex in brain tumours. Amide proton transfer-weighted (APT) imaging is a chemical exchange saturation transfer (CEST) MRI technique that may improve diagnostic accuracy during radiological follow-up. This systematic review and meta-analysis elucidated the level of evidence and details of state-of-the-art imaging for APT-CEST in glioma and brain metastasis surveillance.

Methods: PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for original articles about glioma and metastasis patients who received APT-CEST imaging for suspected TP/TR within 2 years after (chemo)radiotherapy completion. Modified Quality Assessment of Diagnostic Accuracy Studies-2 criteria were applied. A meta-analysis was performed to pool results and to compare subgroups.

Results: Fifteen studies were included for a narrative synthesis, twelve of which (500 patients) were deemed sufficiently homogeneous for a meta-analysis. Magnetisation transfer ratio asymmetry performed well in gliomas (sensitivity 0.88 [0.82-0.92], specificity 0.84 [0.72-0.91]) but not in metastases (sensitivity 0.64 [0.38-0.84], specificity 0.56 [0.33-0.77]). APT-CEST combined with conventional/advanced MRI rendered 0.92 [0.86-0.96] and 0.88 [0.72-0.95] in gliomas. Tumour type, TR prevalence, sex, and acquisition protocol were sources of significant inter-study heterogeneity in sensitivity (I2 = 62.25%; p < 0.01) and specificity (I2 = 66.31%; p < 0.001).

Conclusion: A growing body of literature suggests that APT-CEST is a promising technique for improving the discrimination of TP/TR from TRC in gliomas, with limited data on metastases.

Clinical relevance statement: This meta-analysis identified a utility for APT-CEST imaging regarding the non-invasive discrimination of brain tumour progression from therapy-related changes, providing a critical evaluation of sequence parameters and cut-off values, which can be used to improve response assessment and patient outcome.

Key points: Therapy-related changes mimicking progression complicate brain tumour treatment. Amide proton imaging improves the non-invasive discrimination of glioma progression from therapy-related changes. Magnetisation transfer ratio asymmetry measurement seems not to have added value in brain metastases.

目的:区分脑肿瘤的真正进展或复发(TP/TR)与治疗相关变化(TRC)非常复杂。酰胺质子转移加权(APT)成像是一种化学交换饱和转移(CEST)磁共振成像技术,可提高放射随访的诊断准确性。这篇系统综述和荟萃分析阐明了APT-CEST在胶质瘤和脑转移瘤监测中的证据水平和最新成像技术的细节:系统检索了PubMed、EMBASE、Web of Science和Cochrane图书馆中有关胶质瘤和转移瘤患者的原始文章,这些患者在(化疗)放疗结束后2年内因怀疑TP/TR而接受了APT-CEST成像。采用了 "诊断准确性研究质量评估-2"(Modified Quality Assessment of Diagnostic Accuracy Studies-2)标准。进行荟萃分析以汇总结果并对亚组进行比较:共纳入 15 项研究进行叙述性综合,其中 12 项研究(500 名患者)被认为具有足够的同质性,可进行荟萃分析。磁化转移比不对称在胶质瘤中表现良好(灵敏度为 0.88 [0.82-0.92],特异性为 0.84 [0.72-0.91]),但在转移瘤中表现不佳(灵敏度为 0.64 [0.38-0.84],特异性为 0.56 [0.33-0.77])。APT-CEST 与常规/高级 MRI 相结合,对胶质瘤的灵敏度为 0.92 [0.86-0.96],特异度为 0.88 [0.72-0.95]。肿瘤类型、TR发生率、性别和采集方案是造成研究间敏感性显著异质性的原因(I2 = 62.25%;P 2 = 66.31%;P 结论:越来越多的文献表明,APT-CEST 是一种很有前途的技术,可提高胶质瘤中 TP/TR 与 TRC 的鉴别能力,但有关转移瘤的数据有限:这项荟萃分析确定了 APT-CEST 成像在无创鉴别脑肿瘤进展与治疗相关变化方面的作用,提供了序列参数和临界值的关键评估,可用于改善反应评估和患者预后:要点:模仿进展的治疗相关变化使脑肿瘤治疗复杂化。酰胺质子成像技术可提高胶质瘤进展与治疗相关变化的无创鉴别能力。磁化传递比不对称测量在脑转移瘤中似乎没有附加价值。
{"title":"Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases.","authors":"Rajeev A Essed, Yeva Prysiazhniuk, Ivar J Wamelink, Aynur Azizova, Vera C Keil","doi":"10.1007/s00330-024-11004-y","DOIUrl":"10.1007/s00330-024-11004-y","url":null,"abstract":"<p><strong>Objectives: </strong>Differentiating true progression or recurrence (TP/TR) from therapy-related changes (TRC) is complex in brain tumours. Amide proton transfer-weighted (APT) imaging is a chemical exchange saturation transfer (CEST) MRI technique that may improve diagnostic accuracy during radiological follow-up. This systematic review and meta-analysis elucidated the level of evidence and details of state-of-the-art imaging for APT-CEST in glioma and brain metastasis surveillance.</p><p><strong>Methods: </strong>PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for original articles about glioma and metastasis patients who received APT-CEST imaging for suspected TP/TR within 2 years after (chemo)radiotherapy completion. Modified Quality Assessment of Diagnostic Accuracy Studies-2 criteria were applied. A meta-analysis was performed to pool results and to compare subgroups.</p><p><strong>Results: </strong>Fifteen studies were included for a narrative synthesis, twelve of which (500 patients) were deemed sufficiently homogeneous for a meta-analysis. Magnetisation transfer ratio asymmetry performed well in gliomas (sensitivity 0.88 [0.82-0.92], specificity 0.84 [0.72-0.91]) but not in metastases (sensitivity 0.64 [0.38-0.84], specificity 0.56 [0.33-0.77]). APT-CEST combined with conventional/advanced MRI rendered 0.92 [0.86-0.96] and 0.88 [0.72-0.95] in gliomas. Tumour type, TR prevalence, sex, and acquisition protocol were sources of significant inter-study heterogeneity in sensitivity (I<sup>2</sup> = 62.25%; p < 0.01) and specificity (I<sup>2</sup> = 66.31%; p < 0.001).</p><p><strong>Conclusion: </strong>A growing body of literature suggests that APT-CEST is a promising technique for improving the discrimination of TP/TR from TRC in gliomas, with limited data on metastases.</p><p><strong>Clinical relevance statement: </strong>This meta-analysis identified a utility for APT-CEST imaging regarding the non-invasive discrimination of brain tumour progression from therapy-related changes, providing a critical evaluation of sequence parameters and cut-off values, which can be used to improve response assessment and patient outcome.</p><p><strong>Key points: </strong>Therapy-related changes mimicking progression complicate brain tumour treatment. Amide proton imaging improves the non-invasive discrimination of glioma progression from therapy-related changes. Magnetisation transfer ratio asymmetry measurement seems not to have added value in brain metastases.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"580-591"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative efficacy and safety of radiofrequency ablation and microwave ablation in benign thyroid nodule treatment: a systematic review and meta-analysis. 射频消融和微波消融治疗甲状腺良性结节的疗效和安全性比较:系统综述和荟萃分析。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-07-24 DOI: 10.1007/s00330-024-10881-7
Hunjong Lim, Se Jin Cho, Jung Hwan Baek

Objective: Ultrasound-guided thermal ablation, including radiofrequency ablation (RFA) and microwave ablation (MWA), has become one of the main options for treating benign thyroid nodules (BTNs). To assess the efficacy of thermal ablation of BTNs, we performed a systematic review and meta-analysis of relevant studies.

Materials and methods: A comprehensive search of MEDLINE, EMBASE, and COCHRANE databases was performed up to September 25, 2023, to identify studies directly comparing RFA and MWA for pathologically proven BTNs and reporting clinical outcomes and complications. Data extraction and quality assessment were independently performed by two radiologists according to PRISMA guidelines. The analysis yielded the serial volume reduction ratios (VRRs) of ablated nodules for up to 12 months, symptom and cosmetic scores, and complications.

Results: This analysis included nine studies with 1305 BTNs treated by RFA and 1276 by MWA. VRRs at 1 month, 3 months, and 6 months were similar between RFA and MWA, but RFA showed a significantly higher VRR (83.3%) than MWA (76.9%) at 12 months (p = 0.02). Complication rates showed no significant difference between the two methods. Symptom and cosmetic scores significantly decreased after ablation, without a significant difference between the methods. Subgroup analysis indicated a significantly higher VRR at 12 months for RFA than for MWA for less experienced investigators (≤ 10 years), but no significant difference for more experienced investigators (> 10 years).

Conclusion: RFA and MWA are both effective and safe methods for treating BTNs. RFA showed a higher VRR at 12 months and seems more suitable for less experienced investigators.

Clinical relevance statement: RFA and MWA are both effective and safe treatments for BTNs, with RFA showing a higher VRR at 12 months. Both methods offer minimally invasive and reliable treatment for thyroid nodules.

Key points: The most effective thermal ablation technique for BTNs remains undetermined. RFA showed a higher VRR at 12 months than MWA. Both techniques are effective for treating thyroid nodules; RFA offers greater benefits, particularly for less experienced investigators.

目的:超声引导下的热消融,包括射频消融(RFA)和微波消融(MWA),已成为治疗甲状腺良性结节(BTNs)的主要选择之一。为了评估热消融治疗良性甲状腺结节的疗效,我们对相关研究进行了系统回顾和荟萃分析:对截至 2023 年 9 月 25 日的 MEDLINE、EMBASE 和 COCHRANE 数据库进行了全面检索,以确定对病理证实的 BTNs 直接比较 RFA 和 MWA 并报告临床结果和并发症的研究。数据提取和质量评估由两名放射科医生根据 PRISMA 指南独立完成。分析结果显示了长达12个月的连续消融结节体积缩小率(VRR)、症状和外观评分以及并发症:该分析包括九项研究,其中有 1305 个 BTN 采用 RFA 治疗,1276 个采用 MWA 治疗。RFA和MWA在1个月、3个月和6个月时的VRR相似,但RFA在12个月时的VRR(83.3%)明显高于MWA(76.9%)(p = 0.02)。两种方法的并发症发生率无明显差异。消融术后症状和外观评分明显下降,但两种方法之间无明显差异。亚组分析表明,对于经验较少的研究者(≤ 10 年),RFA 在 12 个月时的 VRR 明显高于 MWA,但对于经验较多的研究者(> 10 年),两者无明显差异:结论:RFA 和 MWA 都是治疗 BTN 有效且安全的方法。结论:RFA 和 MWA 都是治疗 BTN 的有效且安全的方法,RFA 在 12 个月时的 VRR 较高,似乎更适合经验较少的研究者:RFA和MWA都是治疗BTN的有效且安全的方法,其中RFA在12个月后的VRR更高。两种方法都能为甲状腺结节提供微创、可靠的治疗:要点:治疗BTNs最有效的热消融技术仍未确定。RFA在12个月后的VRR高于MWA。两种技术都能有效治疗甲状腺结节;RFA的优势更大,尤其是对于经验不足的研究人员。
{"title":"Comparative efficacy and safety of radiofrequency ablation and microwave ablation in benign thyroid nodule treatment: a systematic review and meta-analysis.","authors":"Hunjong Lim, Se Jin Cho, Jung Hwan Baek","doi":"10.1007/s00330-024-10881-7","DOIUrl":"10.1007/s00330-024-10881-7","url":null,"abstract":"<p><strong>Objective: </strong>Ultrasound-guided thermal ablation, including radiofrequency ablation (RFA) and microwave ablation (MWA), has become one of the main options for treating benign thyroid nodules (BTNs). To assess the efficacy of thermal ablation of BTNs, we performed a systematic review and meta-analysis of relevant studies.</p><p><strong>Materials and methods: </strong>A comprehensive search of MEDLINE, EMBASE, and COCHRANE databases was performed up to September 25, 2023, to identify studies directly comparing RFA and MWA for pathologically proven BTNs and reporting clinical outcomes and complications. Data extraction and quality assessment were independently performed by two radiologists according to PRISMA guidelines. The analysis yielded the serial volume reduction ratios (VRRs) of ablated nodules for up to 12 months, symptom and cosmetic scores, and complications.</p><p><strong>Results: </strong>This analysis included nine studies with 1305 BTNs treated by RFA and 1276 by MWA. VRRs at 1 month, 3 months, and 6 months were similar between RFA and MWA, but RFA showed a significantly higher VRR (83.3%) than MWA (76.9%) at 12 months (p = 0.02). Complication rates showed no significant difference between the two methods. Symptom and cosmetic scores significantly decreased after ablation, without a significant difference between the methods. Subgroup analysis indicated a significantly higher VRR at 12 months for RFA than for MWA for less experienced investigators (≤ 10 years), but no significant difference for more experienced investigators (> 10 years).</p><p><strong>Conclusion: </strong>RFA and MWA are both effective and safe methods for treating BTNs. RFA showed a higher VRR at 12 months and seems more suitable for less experienced investigators.</p><p><strong>Clinical relevance statement: </strong>RFA and MWA are both effective and safe treatments for BTNs, with RFA showing a higher VRR at 12 months. Both methods offer minimally invasive and reliable treatment for thyroid nodules.</p><p><strong>Key points: </strong>The most effective thermal ablation technique for BTNs remains undetermined. RFA showed a higher VRR at 12 months than MWA. Both techniques are effective for treating thyroid nodules; RFA offers greater benefits, particularly for less experienced investigators.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"612-623"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESR Bridges: building bridges in MSK imaging: dual-energy CT and bone marrow detection-a multidisciplinary view. ESR 桥梁:建立 MSK 成像的桥梁:双能 CT 和骨髓检测--多学科视角。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-07-25 DOI: 10.1007/s00330-024-10892-4
Mario Maas, Felix Müller, Frank Bloemers, Mikael Ploug Boesen
{"title":"ESR Bridges: building bridges in MSK imaging: dual-energy CT and bone marrow detection-a multidisciplinary view.","authors":"Mario Maas, Felix Müller, Frank Bloemers, Mikael Ploug Boesen","doi":"10.1007/s00330-024-10892-4","DOIUrl":"10.1007/s00330-024-10892-4","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"856-858"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the future of artificial intelligence and fracture detection of the spine and extremities-"friend not foe". 引领人工智能与脊柱和四肢骨折检测的未来--"非敌非友"。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-07-29 DOI: 10.1007/s00330-024-10991-2
Ali Guermazi
{"title":"Navigating the future of artificial intelligence and fracture detection of the spine and extremities-\"friend not foe\".","authors":"Ali Guermazi","doi":"10.1007/s00330-024-10991-2","DOIUrl":"10.1007/s00330-024-10991-2","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"859-861"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathological prognostic factors of rectal cancer based on diffusion-weighted imaging, intravoxel incoherent motion, and diffusion kurtosis imaging. 基于扩散加权成像、体内非相干运动和扩散峰度成像的直肠癌病理预后因素。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-08-14 DOI: 10.1007/s00330-024-11025-7
Mi Zhou, Mengyuan Chen, Mingfang Luo, Meining Chen, Hongyun Huang

Objectives: To explore diffusion-weighted imaging (DWI), intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI) for assessing pathological prognostic factors in patients with rectal cancer.

Materials and methods: A total of 162 patients (105 males; mean age of 61.8 ± 13.1 years old) scheduled to undergo radical surgery were enrolled in this prospective study. The pathological prognostic factors included histological differentiation, lymph node metastasis (LNM), and extramural vascular invasion (EMVI). The DWI, IVIM, and DKI parameters were obtained and correlated with prognostic factors using univariable and multivariable logistic regression. Their assessment value was evaluated using receiver operating characteristic (ROC) curve analysis.

Results: Multivariable logistic regression analyses showed that higher mean kurtosis (MK) (odds ratio (OR) = 194.931, p < 0.001) and lower apparent diffusion coefficient (ADC) (OR = 0.077, p = 0.025) were independently associated with poorer differentiation tumors. Higher perfusion fraction (f) (OR = 575.707, p = 0.023) and higher MK (OR = 173.559, p < 0.001) were independently associated with LNMs. Higher f (OR = 1036.116, p = 0.024), higher MK (OR = 253.629, p < 0.001), lower mean diffusivity (MD) (OR = 0.125, p = 0.038), and lower ADC (OR = 0.094, p = 0.022) were independently associated with EMVI. The area under the ROC curve (AUC) of MK for histological differentiation was significantly higher than ADC (0.771 vs. 0.638, p = 0.035). The AUC of MK for LNM positivity was higher than f (0.770 vs. 0.656, p = 0.048). The AUC of MK combined with MD (0.790) was the highest among f (0.663), MK (0.779), MD (0.617), and ADC (0.610) in assessing EMVI.

Conclusion: The DKI parameters may be used as imaging biomarkers to assess pathological prognostic factors of rectal cancer before surgery.

Clinical relevance statement: Diffusion kurtosis imaging (DKI) parameters, particularly mean kurtosis (MK), are promising biomarkers for assessing histological differentiation, lymph node metastasis, and extramural vascular invasion of rectal cancer. These findings suggest DKI's potential in the preoperative assessment of rectal cancer.

Key points: Mean kurtosis outperformed the apparent diffusion coefficient in assessing histological differentiation in resectable rectal cancer. Perfusion fraction and mean kurtosis are independent indicators for assessing lymph node metastasis in rectal cancer. Mean kurtosis and mean diffusivity demonstrated superior accuracy in assessing extramural vascular invasion.

研究目的探讨弥散加权成像(DWI)、体细胞内不连贯运动(IVIM)和弥散峰度成像(DKI)用于评估直肠癌患者的病理预后因素:这项前瞻性研究共纳入 162 名计划接受根治术的患者(105 名男性,平均年龄为 61.8 ± 13.1 岁)。病理预后因素包括组织学分化、淋巴结转移(LNM)和壁外血管侵犯(EMVI)。利用单变量和多变量逻辑回归法获得了 DWI、IVIM 和 DKI 参数,并将其与预后因素相关联。使用接收器操作特征(ROC)曲线分析评估其评估价值:结果:多变量逻辑回归分析表明,平均峰度(MK)越高(几率比(OR)= 194.931,P 结论:DKI 参数可作为预后因素:DKI参数可作为成像生物标志物,在手术前评估直肠癌的病理预后因素:弥散峰度成像(DKI)参数,尤其是平均峰度(MK),是评估直肠癌组织学分化、淋巴结转移和壁外血管侵犯的有前途的生物标志物。这些发现表明,DKI 在直肠癌术前评估中具有潜力:要点:在评估可切除直肠癌的组织学分化方面,平均峰度优于表观扩散系数。灌注分数和平均峰度是评估直肠癌淋巴结转移的独立指标。平均峰度和平均扩散系数在评估壁外血管侵犯方面表现出更高的准确性。
{"title":"Pathological prognostic factors of rectal cancer based on diffusion-weighted imaging, intravoxel incoherent motion, and diffusion kurtosis imaging.","authors":"Mi Zhou, Mengyuan Chen, Mingfang Luo, Meining Chen, Hongyun Huang","doi":"10.1007/s00330-024-11025-7","DOIUrl":"10.1007/s00330-024-11025-7","url":null,"abstract":"<p><strong>Objectives: </strong>To explore diffusion-weighted imaging (DWI), intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI) for assessing pathological prognostic factors in patients with rectal cancer.</p><p><strong>Materials and methods: </strong>A total of 162 patients (105 males; mean age of 61.8 ± 13.1 years old) scheduled to undergo radical surgery were enrolled in this prospective study. The pathological prognostic factors included histological differentiation, lymph node metastasis (LNM), and extramural vascular invasion (EMVI). The DWI, IVIM, and DKI parameters were obtained and correlated with prognostic factors using univariable and multivariable logistic regression. Their assessment value was evaluated using receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>Multivariable logistic regression analyses showed that higher mean kurtosis (MK) (odds ratio (OR) = 194.931, p < 0.001) and lower apparent diffusion coefficient (ADC) (OR = 0.077, p = 0.025) were independently associated with poorer differentiation tumors. Higher perfusion fraction (f) (OR = 575.707, p = 0.023) and higher MK (OR = 173.559, p < 0.001) were independently associated with LNMs. Higher f (OR = 1036.116, p = 0.024), higher MK (OR = 253.629, p < 0.001), lower mean diffusivity (MD) (OR = 0.125, p = 0.038), and lower ADC (OR = 0.094, p = 0.022) were independently associated with EMVI. The area under the ROC curve (AUC) of MK for histological differentiation was significantly higher than ADC (0.771 vs. 0.638, p = 0.035). The AUC of MK for LNM positivity was higher than f (0.770 vs. 0.656, p = 0.048). The AUC of MK combined with MD (0.790) was the highest among f (0.663), MK (0.779), MD (0.617), and ADC (0.610) in assessing EMVI.</p><p><strong>Conclusion: </strong>The DKI parameters may be used as imaging biomarkers to assess pathological prognostic factors of rectal cancer before surgery.</p><p><strong>Clinical relevance statement: </strong>Diffusion kurtosis imaging (DKI) parameters, particularly mean kurtosis (MK), are promising biomarkers for assessing histological differentiation, lymph node metastasis, and extramural vascular invasion of rectal cancer. These findings suggest DKI's potential in the preoperative assessment of rectal cancer.</p><p><strong>Key points: </strong>Mean kurtosis outperformed the apparent diffusion coefficient in assessing histological differentiation in resectable rectal cancer. Perfusion fraction and mean kurtosis are independent indicators for assessing lymph node metastasis in rectal cancer. Mean kurtosis and mean diffusivity demonstrated superior accuracy in assessing extramural vascular invasion.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"979-988"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardizing diffusion-weighted imaging in LI-RADS for diagnosis of hepatocellular carcinoma. 将用于诊断肝细胞癌的 LI-RADS 扩散加权成像标准化。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-08-02 DOI: 10.1007/s00330-024-10925-y
Michele Scialpi, Arianna Evangelisti, Klesta Shehu, Paola Comite, Giuseppe Nazareno Antogiovanni, Giovanni Battista Scalera
{"title":"Standardizing diffusion-weighted imaging in LI-RADS for diagnosis of hepatocellular carcinoma.","authors":"Michele Scialpi, Arianna Evangelisti, Klesta Shehu, Paola Comite, Giuseppe Nazareno Antogiovanni, Giovanni Battista Scalera","doi":"10.1007/s00330-024-10925-y","DOIUrl":"10.1007/s00330-024-10925-y","url":null,"abstract":"","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"695-697"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESR Essentials: response assessment criteria in oncologic imaging-practice recommendations by the European Society of Oncologic Imaging. ESR 要点:肿瘤成像中的反应评估标准--欧洲肿瘤成像学会的实践建议。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-08-13 DOI: 10.1007/s00330-024-11006-w
Giulia A Zamboni, Giovanni Cappello, Damiano Caruso, Sofia Gourtsoyianni, Clemens Cyran, Heinz-Peter Schlemmer, Melvin D'Anastasi, Laure Fournier, Emanuele Neri

Assessing the response to oncological treatments is paramount for determining the prognosis and defining the best treatment for each patient. Several biomarkers, including imaging, can be used, but standardization is fundamental for consistency and reliability. Tumor response evaluation criteria have been defined by international groups for application in pharmaceutical clinical trials evaluating new drugs or therapeutic strategies. RECIST 1.1 criteria are exclusively based on unidimensional lesion measurements; changes in tumor size are used as surrogate imaging biomarkers to correlate with patient outcomes. However, increased tumor size does not always reflect tumor progression. The introduction of immunotherapy has led to the development of new criteria (iRECIST, Level of Evidence (LoE) Ib) that consider the possibility that an increase in disease burden is secondary to the immune response instead of progression, with the new concept of Unconfirmed Progressive Disease (a first progression event which must be confirmed on follow-up). Specific criteria were devised for HCC (mRECIST, LoE IV), which measure only enhancing HCC portions to account for changes after local therapy. For GIST treated with imatinib, criteria were developed to account for the possible increase in size reflecting a response rather than a progression by assessing both tumor size and density on CT (Choi, LoE II). This article provides concise and relevant practice recommendations aimed at general radiologists to help choose and apply the most appropriate criteria for assessing response to treatment in different oncologic scenarios. Though these criteria were developed for clinical trials, they may be applied in clinical practice as a guide for day-to-day interpretation. KEY POINTS: Response evaluation criteria, designed for use in clinical trials, might serve as a surrogate biomarker for overall survival. RECIST 1.1 defines measurable and non-measurable disease among which target lesions and non-target lesions are selected at baseline as reference for follow-ups. Some therapies and/or cancers require the use of different criteria, such as iRECIST, mRECIST, and Choi criteria.

评估对肿瘤治疗的反应对于确定预后和为每位患者确定最佳治疗方案至关重要。可以使用多种生物标志物,包括成像,但标准化是一致性和可靠性的基础。肿瘤反应评估标准已由国际组织定义,用于评估新药或治疗策略的药物临床试验。RECIST 1.1 标准完全基于单维病灶测量;肿瘤大小的变化被用作替代成像生物标志物,与患者预后相关。然而,肿瘤体积的增大并不总是反映肿瘤的进展。免疫疗法的引入导致了新标准(iRECIST,证据级别(LoE)Ib)的制定,该标准考虑了疾病负担的增加继发于免疫反应而非进展的可能性,并提出了 "未确诊进展性疾病"(必须在随访中确认的首次进展事件)这一新概念。针对 HCC(mRECIST,LoE IV)制定了专门的标准,该标准仅测量 HCC 的增强部分,以考虑局部治疗后的变化。对于接受伊马替尼治疗的 GIST,通过评估 CT 上的肿瘤大小和密度(Choi,LoE II),制定了标准来考虑肿瘤增大可能反映的反应而非进展。本文针对普通放射科医生提供了简明而相关的实践建议,以帮助他们选择和应用最合适的标准来评估不同肿瘤情况下的治疗反应。虽然这些标准是为临床试验而制定的,但也可应用于临床实践,作为日常解释的指南。要点:用于临床试验的反应评估标准可作为总生存期的替代生物标志物。RECIST 1.1 定义了可测量和不可测量的疾病,其中靶病变和非靶病变在基线时被选定作为随访的参考。某些疗法和/或癌症需要使用不同的标准,如 iRECIST、mRECIST 和 Choi 标准。
{"title":"ESR Essentials: response assessment criteria in oncologic imaging-practice recommendations by the European Society of Oncologic Imaging.","authors":"Giulia A Zamboni, Giovanni Cappello, Damiano Caruso, Sofia Gourtsoyianni, Clemens Cyran, Heinz-Peter Schlemmer, Melvin D'Anastasi, Laure Fournier, Emanuele Neri","doi":"10.1007/s00330-024-11006-w","DOIUrl":"10.1007/s00330-024-11006-w","url":null,"abstract":"<p><p>Assessing the response to oncological treatments is paramount for determining the prognosis and defining the best treatment for each patient. Several biomarkers, including imaging, can be used, but standardization is fundamental for consistency and reliability. Tumor response evaluation criteria have been defined by international groups for application in pharmaceutical clinical trials evaluating new drugs or therapeutic strategies. RECIST 1.1 criteria are exclusively based on unidimensional lesion measurements; changes in tumor size are used as surrogate imaging biomarkers to correlate with patient outcomes. However, increased tumor size does not always reflect tumor progression. The introduction of immunotherapy has led to the development of new criteria (iRECIST, Level of Evidence (LoE) Ib) that consider the possibility that an increase in disease burden is secondary to the immune response instead of progression, with the new concept of Unconfirmed Progressive Disease (a first progression event which must be confirmed on follow-up). Specific criteria were devised for HCC (mRECIST, LoE IV), which measure only enhancing HCC portions to account for changes after local therapy. For GIST treated with imatinib, criteria were developed to account for the possible increase in size reflecting a response rather than a progression by assessing both tumor size and density on CT (Choi, LoE II). This article provides concise and relevant practice recommendations aimed at general radiologists to help choose and apply the most appropriate criteria for assessing response to treatment in different oncologic scenarios. Though these criteria were developed for clinical trials, they may be applied in clinical practice as a guide for day-to-day interpretation. KEY POINTS: Response evaluation criteria, designed for use in clinical trials, might serve as a surrogate biomarker for overall survival. RECIST 1.1 defines measurable and non-measurable disease among which target lesions and non-target lesions are selected at baseline as reference for follow-ups. Some therapies and/or cancers require the use of different criteria, such as iRECIST, mRECIST, and Choi criteria.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"674-683"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gantry-free cone-beam CT arthrography for diagnosis of scapholunate ligament injuries: accelerating the preoperative work-up in acute wrist trauma.
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 DOI: 10.1007/s00330-025-11405-7
Karsten Sebastian Luetkens, Andreas Steven Kunz, Mila Marie Paul, Stefanie Hölscher-Doht, Henner Huflage, Julius Frederik Heidenreich, Lukas Müller, Thorsten Alexander Bley, Rainer Schmitt, Jan-Peter Grunz

Objective: Combining fluoroscopy and high-resolution cone-beam CT (CBCT) in a multipurpose scanner without a conventional gantry holds the potential for time-saving in musculoskeletal interventions. This study investigated the performance of gantry-free CBCT arthrography in patients with suspected scapholunate ligament (SLL) tears.

Materials and methods: Fifty-five patients (29 men, 46.0 ± 15.3 years) who underwent preoperative gantry-free CBCT arthrography between June 2021 and March 2024 were analyzed retrospectively. Three radiologists assessed CBCT arthrograms for tears of the palmar and dorsal SLL segments. Surgical reports served as the reference standard for calculating indicators of diagnostic accuracy. Interreader agreement was tested by computing Krippendorff α. Radiation dose and examination time were recorded.

Results: Tears of the palmar and dorsal SLL segment were recorded in 25 (45%) and 6 patients (11%), respectively. CBCT arthrography facilitated good sensitivity (range for all readers: 84-92%) and excellent specificity (93-97%) in the assessment of the palmar SLL. For the dorsal SLL, sensitivity (83-100%) and specificity (96-98%) were even higher. Substantial agreement was determined for both the palmar (α = 0.83, 95% CI: 0.74-0.90) and dorsal SLL (0.84, 0.70-0.95). The mean volume CT dose index for CBCT arthrography was 3.2 ± 1.4 mGy. Not requiring patient repositioning, the median time between fluoroscopy-guided contrast injection and CBCT was 3:05 min (2:31-3:50 min).

Conclusion: Gantry-free CBCT arthrography allows for excellent accuracy in the preoperative diagnosis of SLL tears with low radiation dose. The ability to alternate between fluoroscopy and CBCT without repositioning facilitates a "one-stop-shop" approach with short examination time.

Key points: Question Performing fluoroscopy-guided arthrography and high-resolution cone-beam CT without patient repositioning appears advantageous for the preoperative work-up of distal radius fractures with concomitant scapholunate ligament injuries. Findings Gantry-free cone-beam CT arthrography allowed for short examination times and high diagnostic accuracy for either segment of the scapholunate ligament (89-98% versus surgery). Clinical relevance Preoperative assessment of scapholunate instability influences treatment since surgeons can reduce radius fractures and perform osteosynthesis via a dorsal portal to simultaneously stabilize the scapholunate compartment or use an additional dorsal access route for ligament suture and transfixation.

{"title":"Gantry-free cone-beam CT arthrography for diagnosis of scapholunate ligament injuries: accelerating the preoperative work-up in acute wrist trauma.","authors":"Karsten Sebastian Luetkens, Andreas Steven Kunz, Mila Marie Paul, Stefanie Hölscher-Doht, Henner Huflage, Julius Frederik Heidenreich, Lukas Müller, Thorsten Alexander Bley, Rainer Schmitt, Jan-Peter Grunz","doi":"10.1007/s00330-025-11405-7","DOIUrl":"https://doi.org/10.1007/s00330-025-11405-7","url":null,"abstract":"<p><strong>Objective: </strong>Combining fluoroscopy and high-resolution cone-beam CT (CBCT) in a multipurpose scanner without a conventional gantry holds the potential for time-saving in musculoskeletal interventions. This study investigated the performance of gantry-free CBCT arthrography in patients with suspected scapholunate ligament (SLL) tears.</p><p><strong>Materials and methods: </strong>Fifty-five patients (29 men, 46.0 ± 15.3 years) who underwent preoperative gantry-free CBCT arthrography between June 2021 and March 2024 were analyzed retrospectively. Three radiologists assessed CBCT arthrograms for tears of the palmar and dorsal SLL segments. Surgical reports served as the reference standard for calculating indicators of diagnostic accuracy. Interreader agreement was tested by computing Krippendorff α. Radiation dose and examination time were recorded.</p><p><strong>Results: </strong>Tears of the palmar and dorsal SLL segment were recorded in 25 (45%) and 6 patients (11%), respectively. CBCT arthrography facilitated good sensitivity (range for all readers: 84-92%) and excellent specificity (93-97%) in the assessment of the palmar SLL. For the dorsal SLL, sensitivity (83-100%) and specificity (96-98%) were even higher. Substantial agreement was determined for both the palmar (α = 0.83, 95% CI: 0.74-0.90) and dorsal SLL (0.84, 0.70-0.95). The mean volume CT dose index for CBCT arthrography was 3.2 ± 1.4 mGy. Not requiring patient repositioning, the median time between fluoroscopy-guided contrast injection and CBCT was 3:05 min (2:31-3:50 min).</p><p><strong>Conclusion: </strong>Gantry-free CBCT arthrography allows for excellent accuracy in the preoperative diagnosis of SLL tears with low radiation dose. The ability to alternate between fluoroscopy and CBCT without repositioning facilitates a \"one-stop-shop\" approach with short examination time.</p><p><strong>Key points: </strong>Question Performing fluoroscopy-guided arthrography and high-resolution cone-beam CT without patient repositioning appears advantageous for the preoperative work-up of distal radius fractures with concomitant scapholunate ligament injuries. Findings Gantry-free cone-beam CT arthrography allowed for short examination times and high diagnostic accuracy for either segment of the scapholunate ligament (89-98% versus surgery). Clinical relevance Preoperative assessment of scapholunate instability influences treatment since surgeons can reduce radius fractures and perform osteosynthesis via a dorsal portal to simultaneously stabilize the scapholunate compartment or use an additional dorsal access route for ligament suture and transfixation.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of a commercially available CAD-system for lung nodule detection and characterization using CT-scans. 验证利用 CT 扫描检测和描述肺结节的商用 CAD 系统。
IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2025-02-01 Epub Date: 2024-07-23 DOI: 10.1007/s00330-024-10969-0
Jasika Paramasamy, Souvik Mandal, Maurits Blomjous, Ties Mulders, Daniel Bos, Joachim G J V Aerts, Prakash Vanapalli, Vikash Challa, Saigopal Sathyamurthy, Ranjana Devi, Ritvik Jain, Jacob J Visser

Objectives: This study aims to externally validate a commercially available Computer-Aided Detection (CAD)-system for the automatic detection and characterization of solid, part-solid, and ground-glass lung nodules (LN) on CT scans.

Methods: This retrospective study encompasses 263 chest CT scans performed between January 2020 and December 2021 at a Dutch university hospital. All scans were read by a radiologist (R1) and compared with the initial radiology report. Conflicting scans were assessed by an adjudicating radiologist (R2). All scans were also processed by CAD. The standalone performance of CAD in terms of sensitivity and false-positive (FP)-rate for detection was calculated together with the sensitivity for characterization, including texture, calcification, speculation, and location. The R1's detection sensitivity was also assessed.

Results: A total of 183 true nodules were identified in 121 nodule-containing scans (142 non-nodule-containing scans), of which R1 identified 165/183 (90.2%). CAD detected 149 nodules, of which 12 were not identified by R1, achieving a sensitivity of 149/183 (81.4%) with an FP-rate of 49/121 (0.405). CAD's detection sensitivity for solid, part-solid, and ground-glass LNs was 82/94 (87.2%), 42/47 (89.4%), and 25/42 (59.5%), respectively. The classification accuracy for solid, part-solid, and ground-glass LNs was 81/82 (98.8%), 16/42 (38.1%), and 18/25 (72.0%), respectively. Additionally, CAD demonstrated overall classification accuracies of 137/149 (91.9%), 123/149 (82.6%), and 141/149 (94.6%) for calcification, spiculation, and location, respectively.

Conclusions: Although the overall detection rate of this system slightly lags behind that of a radiologist, CAD is capable of detecting different LNs and thereby has the potential to enhance a reader's detection rate. While promising characterization performances are obtained, the tool's performance in terms of texture classification remains a subject of concern.

Clinical relevance statement: Numerous lung nodule computer-aided detection-systems are commercially available, with some of them solely being externally validated based on their detection performance on solid nodules. We encourage researchers to assess performances by incorporating all relevant characteristics, including part-solid and ground-glass nodules.

Key points: Few computer-aided detection (CAD) systems are externally validated for automatic detection and characterization of lung nodules. A detection sensitivity of 81.4% and an overall texture classification sensitivity of 77.2% were measured utilizing CAD. CAD has the potential to increase single reader detection rate, however, improvement in texture classification is required.

研究目的本研究旨在对商用计算机辅助检测(CAD)系统进行外部验证,该系统可自动检测和鉴定 CT 扫描中的实性、部分实性和磨玻璃状肺结节(LN):这项回顾性研究包括 2020 年 1 月至 2021 年 12 月期间在荷兰一家大学医院进行的 263 次胸部 CT 扫描。所有扫描均由一名放射科医生(R1)阅读,并与最初的放射学报告进行比较。有冲突的扫描结果由一名放射科医生(R2)裁定。所有扫描也由计算机辅助诊断系统处理。计算了 CAD 在检测灵敏度和假阳性 (FP) 率方面的独立性能,以及特征描述(包括纹理、钙化、推测和位置)的灵敏度。同时还评估了 R1 的检测灵敏度:结果:在 121 次含有结节的扫描(142 次不含有结节的扫描)中,共发现了 183 个真正的结节,其中 R1 发现了 165/183(90.2%)个。CAD 检测出 149 个结节,其中 12 个未被 R1 识别,灵敏度为 149/183(81.4%),FP-率为 49/121(0.405)。CAD 对实性、部分实性和磨玻璃状 LN 的检测灵敏度分别为 82/94(87.2%)、42/47(89.4%)和 25/42(59.5%)。实性、部分实性和磨玻璃状 LN 的分类准确率分别为 81/82(98.8%)、16/42(38.1%)和 18/25(72.0%)。此外,CAD 对钙化、棘化和位置的总体分类准确率分别为 137/149(91.9%)、123/149(82.6%)和 141/149(94.6%):虽然该系统的总体检测率略低于放射科医生,但 CAD 能够检测不同的 LN,因此有可能提高读者的检测率。虽然计算机辅助诊断系统在特征描述方面表现出色,但该工具在纹理分类方面的表现仍然令人担忧:目前市面上有许多肺结节计算机辅助检测系统,其中一些系统仅根据其对实体结节的检测性能进行了外部验证。我们鼓励研究人员结合所有相关特征(包括部分实性结节和磨玻璃结节)来评估其性能:要点:很少有计算机辅助检测(CAD)系统经过外部验证可用于肺结节的自动检测和定性。利用 CAD 测得的检测灵敏度为 81.4%,总体纹理分类灵敏度为 77.2%。CAD 有可能提高单个读者的检测率,但还需要改进纹理分类。
{"title":"Validation of a commercially available CAD-system for lung nodule detection and characterization using CT-scans.","authors":"Jasika Paramasamy, Souvik Mandal, Maurits Blomjous, Ties Mulders, Daniel Bos, Joachim G J V Aerts, Prakash Vanapalli, Vikash Challa, Saigopal Sathyamurthy, Ranjana Devi, Ritvik Jain, Jacob J Visser","doi":"10.1007/s00330-024-10969-0","DOIUrl":"10.1007/s00330-024-10969-0","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to externally validate a commercially available Computer-Aided Detection (CAD)-system for the automatic detection and characterization of solid, part-solid, and ground-glass lung nodules (LN) on CT scans.</p><p><strong>Methods: </strong>This retrospective study encompasses 263 chest CT scans performed between January 2020 and December 2021 at a Dutch university hospital. All scans were read by a radiologist (R1) and compared with the initial radiology report. Conflicting scans were assessed by an adjudicating radiologist (R2). All scans were also processed by CAD. The standalone performance of CAD in terms of sensitivity and false-positive (FP)-rate for detection was calculated together with the sensitivity for characterization, including texture, calcification, speculation, and location. The R1's detection sensitivity was also assessed.</p><p><strong>Results: </strong>A total of 183 true nodules were identified in 121 nodule-containing scans (142 non-nodule-containing scans), of which R1 identified 165/183 (90.2%). CAD detected 149 nodules, of which 12 were not identified by R1, achieving a sensitivity of 149/183 (81.4%) with an FP-rate of 49/121 (0.405). CAD's detection sensitivity for solid, part-solid, and ground-glass LNs was 82/94 (87.2%), 42/47 (89.4%), and 25/42 (59.5%), respectively. The classification accuracy for solid, part-solid, and ground-glass LNs was 81/82 (98.8%), 16/42 (38.1%), and 18/25 (72.0%), respectively. Additionally, CAD demonstrated overall classification accuracies of 137/149 (91.9%), 123/149 (82.6%), and 141/149 (94.6%) for calcification, spiculation, and location, respectively.</p><p><strong>Conclusions: </strong>Although the overall detection rate of this system slightly lags behind that of a radiologist, CAD is capable of detecting different LNs and thereby has the potential to enhance a reader's detection rate. While promising characterization performances are obtained, the tool's performance in terms of texture classification remains a subject of concern.</p><p><strong>Clinical relevance statement: </strong>Numerous lung nodule computer-aided detection-systems are commercially available, with some of them solely being externally validated based on their detection performance on solid nodules. We encourage researchers to assess performances by incorporating all relevant characteristics, including part-solid and ground-glass nodules.</p><p><strong>Key points: </strong>Few computer-aided detection (CAD) systems are externally validated for automatic detection and characterization of lung nodules. A detection sensitivity of 81.4% and an overall texture classification sensitivity of 77.2% were measured utilizing CAD. CAD has the potential to increase single reader detection rate, however, improvement in texture classification is required.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"1076-1088"},"PeriodicalIF":4.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Radiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1